
Hugo C Turner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6428580/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health, The, 2016, 1, e8-e17.	10.0	210
2	Adjusting for Inflation and Currency Changes Within Health Economic Studies. Value in Health, 2019, 22, 1026-1032.	0.3	151
3	Should the Goal for the Treatment of Soil Transmitted Helminth (STH) Infections Be Changed from Morbidity Control in Children to Community-Wide Transmission Elimination?. PLoS Neglected Tropical Diseases, 2015, 9, e0003897.	3.0	108
4	Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: a systematic review. Parasites and Vectors, 2016, 9, 29.	2.5	94
5	Soil-Transmitted Helminths. Advances in Parasitology, 2016, 94, 133-198.	3.2	84
6	Reaching the London Declaration on Neglected Tropical Diseases Goals for Onchocerciasis: An Economic Evaluation of Increasing the Frequency of Ivermectin Treatment in Africa. Clinical Infectious Diseases, 2014, 59, 923-932.	5.8	82
7	Are We on Our Way to Achieving the 2020 Goals for Schistosomiasis Morbidity Control Using Current World Health Organization Guidelines?. Clinical Infectious Diseases, 2018, 66, S245-S252.	5.8	82
8	Achieving affordable critical care in low-income and middle-income countries. BMJ Global Health, 2019, 4, e001675.	4.7	77
9	Prevalence and causes of vision loss in sub-Saharan Africa: 1990–2010. British Journal of Ophthalmology, 2014, 98, 612-618.	3.9	75
10	River Blindness. Advances in Parasitology, 2016, 94, 247-341.	3.2	66
11	The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data. Parasites and Vectors, 2015, 8, 167.	2.5	62
12	Cost and cost-effectiveness of soil-transmitted helminth treatment programmes: systematic review and research needs. Parasites and Vectors, 2015, 8, 355.	2.5	58
13	Interrupting transmission of soil-transmitted helminths: a study protocol for cluster randomised trials evaluating alternative treatment strategies and delivery systems in Kenya. BMJ Open, 2015, 5, e008950.	1.9	56
14	Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections. Parasites and Vectors, 2014, 7, 241.	2.5	55
15	Epidemiological surveys of, and research on, soil-transmitted helminths in Southeast Asia: a systematic review. Parasites and Vectors, 2016, 9, 31.	2.5	54
16	Economic Considerations for Moving beyond the Kato-Katz Technique for Diagnosing Intestinal Parasites As We Move Towards Elimination. Trends in Parasitology, 2017, 33, 435-443.	3.3	54
17	What is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection?. Parasites and Vectors, 2015, 8, 553.	2.5	52
18	Uncertainty Surrounding Projections of the Long-Term Impact of Ivermectin Treatment on Human Onchocerciasis. PLoS Neglected Tropical Diseases, 2013, 7, e2169.	3.0	50

HUGO C TURNER

#	Article	IF	CITATIONS
19	Cost-effectiveness of scaling up mass drug administration for the control of soil-transmitted helminths: a comparison of cost function and constant costs analyses. Lancet Infectious Diseases, The, 2016, 16, 838-846.	9.1	49
20	Assessing the interruption of the transmission of human helminths with mass drug administration alone: optimizing the design of cluster randomized trials. Parasites and Vectors, 2017, 10, 93.	2.5	49
21	An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations. Frontiers in Public Health, 2021, 9, 722927.	2.7	49
22	The Estimates of the Health and Economic Burden of Dengue in Vietnam. Trends in Parasitology, 2018, 34, 904-918.	3.3	47
23	An economic evaluation of expanding hookworm control strategies to target the whole community. Parasites and Vectors, 2015, 8, 570.	2.5	44
24	The design of schistosomiasis monitoring and evaluation programmes: The importance of collecting adult data to inform treatment strategies for Schistosoma mansoni. PLoS Neglected Tropical Diseases, 2018, 12, e0006717.	3.0	44
25	The Cost of Annual versus Biannual Community-Directed Treatment of Onchocerciasis with Ivermectin: Ghana as a Case Study. PLoS Neglected Tropical Diseases, 2013, 7, e2452.	3.0	41
26	The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000–2014). Infectious Diseases of Poverty, 2016, 5, 54.	3.7	37
27	Evaluating the variation in the projected benefit of community-wide mass treatment for schistosomiasis: Implications for future economic evaluations. Parasites and Vectors, 2017, 10, 213.	2.5	37
28	Analysis of the population-level impact of co-administering ivermectin with albendazole or mebendazole for the control and elimination of Trichuris trichiura. Parasite Epidemiology and Control, 2016, 1, 177-187.	1.8	35
29	The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs. Clinical Infectious Diseases, 2020, 70, 2561-2567.	5.8	34
30	Neglected tools for neglected diseases: mathematical models in economic evaluations. Trends in Parasitology, 2014, 30, 562-570.	3.3	31
31	Investment success in public health: An analysis of the cost-effectiveness and cost-benefit of the Global Programme to Eliminate Lymphatic Filariasis. Clinical Infectious Diseases, 2016, 64, ciw835.	5.8	31
32	Comparison and validation of two mathematical models for the impact of mass drug administration on Ascaris lumbricoides and hookworm infection. Epidemics, 2017, 18, 38-47.	3.0	31
33	Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs. Parasites and Vectors, 2018, 11, 75.	2.5	30
34	Human Onchocerciasis: Modelling the Potential Long-term Consequences of a Vaccination Programme. PLoS Neglected Tropical Diseases, 2015, 9, e0003938.	3.0	28
35	Vaccine-preventable diseases in lower-middle-income countries. Lancet Infectious Diseases, The, 2018, 18, 937-939.	9.1	27
36	Economic Evaluations of Mass Drug Administration: The Importance of Economies of Scale and Scope. Clinical Infectious Diseases, 2018, 66, 1298-1303.	5.8	26

HUGO C TURNER

#	Article	lF	CITATIONS
37	Achieving Elimination as a Public Health Problem for Schistosoma mansoni and S. haematobium: When Is Community-Wide Treatment Required?. Journal of Infectious Diseases, 2020, 221, S525-S530.	4.0	26
38	Understanding Heterogeneity in the Impact of National Neglected Tropical Disease Control Programmes: Evidence from School-Based Deworming in Kenya. PLoS Neglected Tropical Diseases, 2015, 9, e0004108.	3.0	24
39	Vaccinating Women Previously Exposed to Human Papillomavirus: A Cost-Effectiveness Analysis of the Bivalent Vaccine. PLoS ONE, 2013, 8, e75552.	2.5	19
40	Optimising cluster survey design for planning schistosomiasis preventive chemotherapy. PLoS Neglected Tropical Diseases, 2017, 11, e0005599.	3.0	19
41	100 Years of Mass Deworming Programmes: A Policy Perspective From the World Bank's Disease Control Priorities Analyses. Advances in Parasitology, 2018, 100, 127-154.	3.2	19
42	Economic Burden Attributed to Children Presenting to Hospitals With Hand, Foot, and Mouth Disease in Vietnam. Open Forum Infectious Diseases, 2019, 6, .	0.9	19
43	Economic evaluations of onchocerciasis interventions: a systematic review and research needs. Tropical Medicine and International Health, 2019, 24, 788-816.	2.3	19
44	The Uncertainty Surrounding the Burden of Post-acute Consequences of Dengue Infection. Trends in Parasitology, 2019, 35, 673-676.	3.3	18
45	Determining post-treatment surveillance criteria for predicting the elimination of Schistosoma mansoni transmission. Parasites and Vectors, 2019, 12, 437.	2.5	16
46	Economic evaluations of human schistosomiasis interventions: a systematic review and identification of associated research needs. Wellcome Open Research, 2020, 5, 45.	1.8	16
47	Economic evaluations of human schistosomiasis interventions: a systematic review and identification of associated research needs. Wellcome Open Research, 2020, 5, 45.	1.8	15
48	Productivity costs from a dengue episode in Asia: a systematic literature review. BMC Infectious Diseases, 2020, 20, 393.	2.9	14
49	Are current preventive chemotherapy strategies for controlling and eliminating neglected tropical diseases cost-effective?. BMJ Global Health, 2021, 6, e005456.	4.7	14
50	The health and economic burden of podoconiosis in Ethiopia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 114, 284-292.	1.8	12
51	Valuing the Unpaid Contribution of Community Health Volunteers to Mass Drug Administration Programs. Clinical Infectious Diseases, 2019, 68, 1588-1595.	5.8	11
52	Mass Deworming Programs in Middle Childhood and Adolescence. , 2017, , 165-182.		11
53	Projected costs associated with school-based screening to inform deployment of Dengvaxia: Vietnam as a case study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2018, 112, 369-377.	1.8	10
54	Intrathecal Immunoglobulin for treatment of adult patients with tetanus: A randomized controlled 2x2 factorial trial. Wellcome Open Research, 2018, 3, 58.	1.8	10

HUGO C TURNER

#	Article	IF	CITATIONS
55	Programmatic implications of the TUMIKIA trial on community-wide treatment for soil-transmitted helminths: further health economic analyses needed before a change in policy. Parasites and Vectors, 2020, 13, 102.	2.5	9
56	Vaccination or mass drug administration against schistosomiasis: a hypothetical cost-effectiveness modelling comparison. Parasites and Vectors, 2019, 12, 499.	2.5	8
57	High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. Open Forum Infectious Diseases, 2021, 8, ofab267.	0.9	6
58	Human versus equine intramuscular antitoxin, with or without human intrathecal antitoxin, for the treatment of adults with tetanus: a 2â€^×â€^2 factorial randomised controlled trial. The Lancet Global Health, 2022, 10, e862-e872.	6.3	6
59	Direct Medical Costs of Tetanus, Dengue, and Sepsis Patients in an Intensive Care Unit in Vietnam. Frontiers in Public Health, 0, 10, .	2.7	6
60	Intrathecal Immunoglobulin for treatment of adult patients with tetanus: A randomized controlled 2x2 factorial trial. Wellcome Open Research, 2018, 3, 58.	1.8	5
61	Towards a fair and transparent research participant compensation and reimbursement framework in Vietnam. International Health, 2020, 12, 533-540.	2.0	4
62	The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam. Wellcome Open Research, 2019, 4, 129.	1.8	4
63	The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam. Wellcome Open Research, 2019, 4, 129.	1.8	4
64	Health economic analyses of the Global Programme to Eliminate Lymphatic Filariasis. International Health, 2020, 13, S71-S74.	2.0	4
65	A refined and updated health impact assessment of the Global Programme to Eliminate Lymphatic Filariasis (2000–2020). Parasites and Vectors, 2022, 15, .	2.5	3
66	Cost-effectiveness of community-wide treatment for helminthiasis. The Lancet Global Health, 2016, 4, e156.	6.3	2
67	Are current preventive chemotherapy strategies for controlling and eliminating neglected tropical diseases cost-effective?. BMJ Global Health, 2021, 6, .	4.7	2
68	Study protocol: The clinical features, epidemiology, and causes of paediatric encephalitis in southern Vietnam. Wellcome Open Research, 0, 6, 133.	1.8	0
69	Study protocol: The clinical features, epidemiology, and causes of paediatric encephalitis in southern Vietnam. Wellcome Open Research, 0, 6, 133.	1.8	0